Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

被引：0

作者：

Lu, S. ^{[1
]}

Cheng, Y. ^{[2
]}

Huang, D. ^{[3
]}

Sun, Y. ^{[4
]}

Wu, L. ^{[5
]}

Zhou, C. ^{[6
]}

Zhou, J. ^{[7
]}

Guo, Y. ^{[8
]}

Chen, L. ^{[9
]}

Shao, J. ^{[9
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Caner Ctr, Shanghai, Peoples R China

[2] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China

[3] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China

[4] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China

[5] Hunan Canc Hosp, Dept Thorac Med 2, Changsha, Peoples R China

[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Resp Med Dept, ffiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China

[7] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China

[8] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Med Oncol, Shanghai, Peoples R China

[9] Eli Lilly & Co, Oncol, Shanghai, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期

关键词：

Selpercatinib; RET fusion-positive NSCLC; China; ORR;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA02.01

引用

页码：S888 / S889

页数：2

共 50 条

[1] Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
Lu, Shun
Cheng, Ying
Huang, Dingzhi
Sun, Yuping
Wu, Lin
Zhou, Chengzhi
Guo, Ye
Shao, Jingxin
Zhang, Wanli
Zhou, Jianying
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[2] The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
Ke, Jun-yi
Huang, Shu
Jing, Zhi-tao
Duan, Min-chao
INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 768 - 776
[3] The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
Jun-yi Ke
Shu Huang
Zhi-tao Jing
Min-chao Duan
Investigational New Drugs, 2023, 41 : 768 - 776
[4] RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
Novello, Silvia
Califano, Raffaele
Reinmuth, Niels
Tamma, Antonella
Puri, Tarun
ONCOLOGIST, 2023, 28 (05) : 402 - 413
[5] Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial
Minchom, Anna
Tan, Aaron C.
Massarelli, Erminia
Subbiah, Vivek
Boni, Valentina
Robinson, Bruce
Wirth, Lori J.
Hess, Lisa M.
Jen, Min-Hua
Kherani, Jennifer
Olek, Elizabeth
McCoach, Caroline E.
ONCOLOGIST, 2022, 27 (01) : 22 - 29
[6] Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
Fangdi Sun
Caroline E. McCoach
Current Treatment Options in Oncology, 2021, 22
[7] Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
Sun, Fangdi
McCoach, Caroline E.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (08)
[8] Selpercatinib in Chinese patients with RET-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial
Lu, Shun
Cheng, Ying
Huang, Dingzhi
Sun, Yuping
Wu, Lin
Zhou, Chengzhi
Zhou, Jianying
Guo, Ye
Shao, Jingxin
Zhang, Wanli
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
[9] Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
Illini, Oliver
Hochmair, Maximilian Johannes
Fabikan, Hannah
Weinlinger, Christoph
Tufman, Amanda
Swalduz, Aurelie
Lamberg, Kristina
Hashemi, Sayed M. S.
Huemer, Florian
Vikstrom, Anders
Wermke, Martin
Absenger, Gudrun
Addeo, Alfredo
Banerji, Shantanu
Calles, Antonio
Clarke, Stephen
Di Maio, Massimo
Durand, Alice
Duruisseaux, Michael
Itchins, Malinda
Kaaranien, Okko-Sakari
Krenn, Florian
Laack, Eckart
de Langen, Adrianus Johannes
Mohorcic, Katja
Pall, Georg
Passaro, Antonio
Prager, Gerald
Rittmeyer, Achim
Rothenstein, Jeffrey
Schumacher, Michael
Woell, Ewald
Valipour, Arschang
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[10] Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion-positive non-small cell lung cancer: a case report
Scattolin, Daniela
Scagliori, Elena
Scapinello, Antonio
Fantin, Alberto
Guarneri, Valentina
Pasello, Giulia
FRONTIERS IN ONCOLOGY, 2023, 13

← 1 2 3 4 5 →